Diabetes Mellitus Clinical Trial
Official title:
Genetic and Environmental Risk Factors of Type 1 Autoimmune Diabetes and Its Early Complications. French Multicentric Cohort of Diabetic Patients.
The aim of this study is to complete the identification of genetic factors (G) and to
undertake the search of environmental factors (E) predisposing to type 1 diabetes (T1D) by
constituting a cohort of 3500 T1D patients and a control cohort. We will use the base of G
analysis (whole genome genotyping done once a patient using methods conually updated at
Centre National de Genotype) and innovative E analysis to develop the following long term
objectives :
- Identify G and E factors influencing the process of remaining beta cells' destruction
during the first 3 years after diagnosis (subgroup of T1D patients with a 0-3 years
diabetes duration);
- Identify G factors (pharmacogenomics) of the individual response to insulin using the
effective insulin dose as a phenotype over a period of 2 years (subgroup of T1D
patients with negative C-peptide and well managed diabetes);
- Undertake a prospective research of G and E risk factors of "death in bed" syndrome in
diabetic adolescents;
- Undertake a prospective research of G and E risk factors of incipient glomerular
microangiopathy (regule measurement of microalbuminuria).
Still recognized in youth only at a stage of complete beta-cell mass destruction and insulin
deficiency, autoimmune T1D remains a source of major morbidity through daily life and
chronic angiopathic complications despite a better glycemic control. T1D onset is now
predominantly pediatric, since its incidence shows a rapid and continuous increase in young
European children, due to unknown emerging environmental changes, creating a major need for
discoveries in the environmental field. Finding avoidable E factors can allow T1D prevention
in the whole children population. Lack of infectious exposures ("the hygiene hypothesis"),
viruses, early nutrition, or other factors have been suspected, but E causes of T1D remain a
black box, as for most human diseases, that should now be approached more systematically and
with respect to gene-environment interactions.
The aim of our study is to complete the identification of genetic factors (G) and to
undertake the search of environmental factors (E) predisposing to type 1 diabetes (T1D) by
constituting a cohort of 3500 T1D patients and a control cohort. We will use the base of G
analysis (whole genome genotyping done once a patient using methods conually updated at
Centre National de Genotype) and innovative E analysis to develop the following long term
objectives :
- Identify G and E factors influencing the process of remaining beta cells' destruction
during the first 3 years after diagnosis (subgroup of T1D patients with a 0-3 years
diabetes duration);
- Identify G factors (pharmacogenomics) of the individual response to insulin using the
effective insulin dose as a phenotype over a period of 2 years (subgroup of T1D
patients with negative C-peptide and well managed diabetes);
- Undertake a prospective research of G and E risk factors of "death in bed" syndrome in
diabetic adolescents;
- Undertake a prospective research of G and E risk factors of incipient glomerular
microangiopathy (regule measurement of microalbuminuria).
We propose to constitute a French multicentric cohort of T1D patients, well phenotyped by 3
data types : genetic, environmental and clinical data. The data collection scheme includes
at entry a comprehensive 850 items environmental questionnaire for all subjects and a full
genotyping with at least 500,000 SNPs until whole-genome sequencing can be deployed by
CNG-CEA. Every 6 months, a standardized clinical assessment is made in patients (a WEB
application ensuring this standardization has already been developed). Personal address(es)
will be collected and geocoded, then mapped with environmental geographic information
systems (GIS).
With environmental modelling, the high dimensionality analyses (HDA) constitutes one of the
main originality of ISIS-DIAB approaches of translational research. HDA will face not only a
massive mass of data, but data of a remarkable diversity (genomic variants, environmental
items from questionnaires, environmental data bases mapped to patient address, space-time
items, characteristics of social environment, clinical phenotypes etc). A given genotype
(defined by many genomic variants) will predispose to T1D only in a given environmental
context (defined possibly by a number of factors) and induce a given type of autoimmune
process (age of onset, rate of destruction, biomarkers). Since T1D is both multifactorial
and heterogeneous, causal factors may interact in a considerable number of scenarii, thus
platforms which study these factors should obviously interact. Without HDA, each platform
would be left faced with its own data. The chef d'orchestre has to be HDA, to integrate the
massive amounts of data and draw networks of causality. Technological advances in HDA
developed in other fields of sciences, business and economics (forecasting technology) will
be transferred to biomedical research through ISIS-DIAB. French have a strong tradition of
high-level maths in this area. We designed the ISIS-DIAB cohort and collection of data to
feed HDA with multidisciplinary data. In ISIS-DIAB program, HDA will identify the variables
that have the most predictive value on several outcomes (not confined to T1D causality).
;
Observational Model: Case Control
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |